ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses

Archives of Internal Medicine

Volumn 169, Issue 19, 2009, Pages 1810-

  Onuigbo, Macaulay A C ^a  

^a Mayo Health System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; RAMIPRIL; TELMISARTAN; THIAZIDE DIURETIC AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; HEART INFARCTION; HUMAN; KIDNEY FAILURE; LETTER; MONOTHERAPY; PRIORITY JOURNAL; CHEMICALLY INDUCED DISORDER; CHRONIC KIDNEY FAILURE; DRUG COMBINATION; META ANALYSIS; NOTE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; CHLORTHALIDONE; CLINICAL TRIALS AS TOPIC; DIABETES COMPLICATIONS; DRUG THERAPY, COMBINATION; HUMANS; KIDNEY FAILURE; KIDNEY FAILURE, CHRONIC; META-ANALYSIS AS TOPIC; MYOCARDIAL INFARCTION; SODIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 70350504141     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2009.371     Document Type: Letter

References (6)

1. Wright JT Jr, Probstfield JL, Cushman WC, et al; ALLHAT Collaborative Research Group. ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med. 2009;169(9):832-842.
2. Yusuf S, Teo KK, Pogue J, et al;ONTARGETInvestigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358 (15):1547-1559.
3. Onuigbo MAC. Reno-prevention vs reno-protection: a critical re-appraisal of the evidence-base from the large RAAS blockade trials after ONTARGET-a call for more circumspection. QJM. 2009;102(3):155-167.
4. Onuigbo MAC. Analytical review of the evidence for renoprotection by reninangiotensin- aldosterone system blockade in chronic kidney disease-a call for caution. Nephron Clin Pract. 2009;113(2):c63-c70.
5. Suissa S, Hutchinson T, Brophy JM, Kezouh A. ACE-inhibitor use and the long-term risk of renal failure in diabetes. Kidney Int. 2006;69(5):913-919. (Pubitemid 43297904)
6. Mann JF, Schmieder RE, McQueen M, et al; ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372(9638):547-553.